House
Sign inCreate account
Drug lookup
Drug reference

delgocitinib

Pan-JAK inhibitor · Immunosuppressant

Pan-JAK inhibitorImmunosuppressant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated

Mechanism

Not yet extracted

Contraindications

  • nonuse during breastfeeding
  • concurrent use of live vaccines

Side effects

Common
thrombocytopeniaanemianeutropeniaincreased risk of infections (upper respiratory, sinus, common cold, hepatitis c virus)
Serious
  • increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death
  • higher rate of all-cause mortality, including sudden cardiovascular death
  • higher rate of certain cancers
  • higher rate of thrombosis, cardiovascular death, myocardial infarction, and stroke

Related guidelines

Heart failure in diabetes
RSSDI · Cardiology · 2023
Hypertension in adults
ICMR · Cardiology · 2019
Hypertrophic cardiomyopathy
ESC · Cardiology · 2026
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022
Type 2 diabetes in adults
NICE · Endocrinology · 2022

Ask House about delgocitinib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team